The popularity of copyright’s blockbuster initially fueled a surge for pharma, however recent shifts present a uncertain scenario for investors. Off-patent alternatives are reducing earnings, and ongoing litigation https://umairfepz807324.total-blog.com/the-blue-pill-and-big-pharma-a-volatile-play-66696184